

Résumé

Xuezhong Alex Yang, M.D.

BOARD CERTIFICATION:

2013: ABIM-Certified for Hematology
2013: ABIM-Certified for Medical Oncology
2009: ABIM-Certified for Internal Medicine

MEDICAL LICENSURE:

2006: Washington DC
2012: South Carolina

CLINICAL TRAINING:

2009 – 2012 Clinical Fellow, Lombardi Cancer Center, Georgetown University Hospital, Washington, DC
2006 – 2009 Resident, Georgetown University/Washington Hospital Center Medicine Program, Washington, DC

EDUCATION:

1988 – 1995: China Medical University, Shenyang, China.
Degree Obtained: M.D.
Master of Medical Research
1998 – 2003: Postdoctoral Fellow, National Cancer Institute, NIH, Bethesda, MD

WORKING EXPERIENCE:

2012 – Now Oncologist, Upstate Oncology Associates, Bon Secours Health System St. Francis Hospital, Greenville, SC
2009 – 2012 Clinical Fellow, Lombardi Cancer Center, Georgetown University Hospital, Washington, DC
2006 – 2009 Resident, Georgetown University/Washington Hospital Center Medicine Program, Washington, DC
2003 – 2006 Research Fellow, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD
1998 – 2003 Visiting Fellow, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD
1997 – 1998 Assistant Professor, Laboratory of Hematology, The 2nd Affiliated Hospital, China Medical University, Shenyang

1995 – 1997 Research Associate, Laboratory of Hematology, The 2nd Affiliated Hospital, China Medical University, Shenyang

COMMITTEES & OTHER OFFICES:

Cancer Care Committee at Bon Secours St. Francis Health System

Utilization Review and Medical Record Committee at Bon Secours SF Health System

PROFESSIONAL SOCIETIES:

American Society of Clinical Oncology

American Society of Hematology

American Medical Association

PEER REVIEWED PUBLICATIONS COAUTHORSHIP:

1. SL-401, a targeted therapy directed to the interleukin-3 receptor, produces remissions in patients with blastic plasmacytoid dendritic cell neoplasm, *Blood*, submitted
2. Maintenance therapy with capecitabine in patients with resected pancreatic adenocarcinoma after adjuvant therapy, a retrospective cohort study, *Gastrointest Cancer Res.* 2014 Jan-Feb; 7(1): 38
3. CASZ1, a candidate tumor-suppressor gene, suppresses neuroblastoma tumor growth through reprogramming gene expression, *Cell Death Differ*, 2011 Jul; 18(7):1174-83
4. Molecular cloning and characterization of human Castor, a novel human gene upregulated during cell differentiation. *Biochem Biophys Res Commun*, 2006 Jun 9;344(3):834-44
5. The Sensitivity of TNF-Related Apoptosis-Inducing Ligand in Neuroblastoma Is Increased by Higher N-myc Level and Not Blocked by BDNF/TrkB Activation, *World Journal of Pediatrics*, 2006 (2): 187-194
6. Pediatric Pancreatoblastoma: Cytogenetic and pathologic characterization of tumor and derived cell line, *Cancer Genetics and Cytogenetics*, 2005 (157): 109-117
7. Interferon Enhances the Effectiveness of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Agonists in a Xenograft Model of Ewing's Sarcoma, *Cancer Research*, 2004 (64): 8349-8356.
8. Induction of caspase 8 by IFN- γ renders some NB cells TRAIL sensitive but reveals a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB. *Cancer Research*, 2003 (63): 1122-1129.
9. Targeting the TRAIL path in neuroblastoma, *Cancer Letters*, 2003 (197): 137-143.
10. Comparative study of imaging modalities in localization of occult neuroblastoma. *Chin J Med Imaging*, 6(2), 1998: 109-111.

11. N-myc Amplification Quantification and Ocular Metastasis of Neuroblastoma. *Chin J Pediatr*, May 1998, 36(5): 270-271.
12. N-myc Amplification Quantification and Clinical Outcome of Neuroblastoma, by Differential-PCR. *Chin J Pediatr Surgery*, Aug., 1996, vol.17, No.4, 195-198.
13. Quality of Life -- Perspectives and Methods. *Clinical Epidemiology*, edition2, 1995, Zhongxing Sun, 344-349

INVITED LECTURES AT NATIONAL AND INTERNATIONAL MEETINGS

1. Conference on Advances in Neuroblastoma Research, **Los Angles, CA, May 2006**, *Loss of NB Suppressor hCas via 1pLOH and N-myc Suppression, A Tale Updated*, Oral Presentation
2. American Association for Cancer Research (AACR) 96th Annual Meeting, **Anaheim, CA, April 2005**, *A Tale of Two Hits: hCas Loss via 1pLOH and N-myc Repression*, Oral Presentation
3. Conference on Advances in Neuroblastoma Research, **Paris, France, June 2002**, *A TRAIL of Two Deficiencies: Induction Of Caspase 8 By IFN- γ Renders Some NB Cells TRAIL Sensitive But Reveals A Lack Of Membrane TR1/TR2 Also Contributes To TRAIL Resistance In NB*, Oral Presentation
4. The Second China Neuroblastoma Group Conference, **Shenyang, China, April 2002**, *Sensitize NB Cells to TRAIL Toxicity via Strategies That Restore Multiple Defects of Death Receptor Pathway*, Invited Speaker

POSTER PRESENTATIONS AND ABSTRACTS:

1. ESMO 14th World Congress on GI cancer, Barcelona, June 2012, Survival analysis of maintenance therapy with capecitabine in patients with resected pancreatic adenocarcinoma after adjuvant therapy, a retrospective cohort study
2. ASCO GI Symposium, San Francisco, Jan 2012, Adjuvant Maintenance Capecitabine Treatment in Resectable Pancreatic Carcinoma
3. American Association for Cancer Research (AACR) 96th Annual Meeting, Anaheim, CA, April 2005, A Tale of Two Hits: hCas Loss via 1pLOH and N-myc Repression
4. Conference on Advances in Neuroblastoma Research, Genova, Italy, June 2004, Loss of hCas function, a novel neuroblastoma differentiation related gene, via LOH at chromosome 1p36.22 and functional silencing by N-myc

5. Conference on Advances in Neuroblastoma Research, Paris, France, June 2002, Induction of caspase 8 by IFN- γ renders some NB cells TRAIL sensitive but reveals a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB
6. The Second Conference of Chinese Neuroblastoma Group, Shenyang, China, April, 2002, Identification of TRAIL pathway deficiencies in neuroblastoma
7. The 17th Annual Oncogene Meeting, Fredrick, MD, June, 2001, The Identification of Human Castor Gene, A Novel Neuroblastoma (NB) Differentiation Related Gene on Chromosome 1p36.22
8. The 42nd Annual Meeting of SIOP (International Society of Pediatric Oncology), Amsterdam, Netherlands, October, 2000, Cord blood stem cells transplantation in the treatment of NB
9. International Pediatric Oncology Meeting in Beijing, June, 1997, N-myc Amplification Quantification and Ocular Metastasis of Neuroblastoma